1. In Vivo
  2. >>Archive

Inamed and Medicis Change the Face of the Aesthetic Market

The $2.8 billion merger of Medicis Pharmaceutical Corp. a specialty pharma focusing on dermatology with sales of $303 million, and Inamed Corp., a cosmetic surgery company with sales of $384 million creates the largest plure-play aesthetics company focusing on physician markets, and a base for future consolidation in a fragmented and rapidly growing market.

There's no question that in the US, the market for cosmetic procedures is booming. Prime-time reality TV shows like ABC's "Extreme Makeover" and FOX's "The Swan" seem to suggest that plastic surgery is becoming almost as mainstream as cold cream as a means of beautification, and indeed, that trend is backed up by statistics from the American Society for Aesthetic Plastic Surgery (ASAPS). According to the ASAPS, there were 11.9 million cosmetic procedures in 2004, a 44% increase over 2003, with Botox injections heading the list of procedures, and liposuction the most often performed surgery.

The $2.8 billion merger of Medicis Pharmaceutical Corp. a specialty pharma focusing on dermatology with sales of $303 million,...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo